The landmark results of MADIT II provide hope for survival for many patients with prior myocardial infarction (MI) who
would otherwise become victims of sudden cardiac death (SCD). Even with advancements in preventing recurrent MI and heart failure, SCD remains a major threat. Each year, SCD claims the lives
of 300,000 Americans with 80% to
90% of those deaths caused by
ventricular fibrillation.1,2 Conventional antiarrhythmic drug therapy has proven
to be not as effective in preventing SCD, as demonstrated in MADIT II.3-5
MADIT II was designed to determine if prophylactic implantable cardioverter defibrillator (ICD) therapy in moderately high-risk coronary patients in addition to conventional therapy would significantly reduce death compared with patients treated with conventional therapy alone.
The trial, which began July 11, 1997, was stopped by the Data and Safety Monitoring Board on November 20, 2001, after reaching the pre-specified efficacy boundary. The trial's principal investigator was Arthur J. Moss, MD, professor of medicine at the University of Rochester Medical Center in Rochester, New York.